| Literature DB >> 25101323 |
Tang-Kai Yin1, Bi-Fang Lee2, Yen Kuang Yang3, Nan-Tsing Chiu2.
Abstract
This study was to investigate whether various region-of-interest (ROI) methods for measuring dopamine transporter (DAT) availabilities by single photon emission computed tomography (SPECT) are statistically different, whether results of medical research are thereby influenced, and causes of these differences. Eighty-four healthy adults with (99m)Tc-TRODAT-1 SPECT and magnetic resonance imaging (MRI) scans were included. Six major analysis approaches were compared: (1) ROI drawn on the coregistered MRI; (2) ROIs drawn on the SPECT images; (3) standard ROI templates; (4) threshold-ROIs; (5) atlas-based mappings with coregistered MRI; and (6) atlas-based mappings with SPECT images. Using the atlas-based approaches we assessed the influence of striatum ROIs by slice-wise and voxel-wise comparisons. In (5) and (6), three partial-volume correction (PVC) methods were also explored. The results showed that DAT availabilities obtained from different methods were closely related but quite different and leaded to significant differences in determining the declines of DAT availability per decade (range: 5.95-11.99%). Use of 3D whole-striatum or more transverse slices could avoid biases in measuring the striatal DAT declines per decade. Atlas-based methods with PVC may be the preferable methods for medical research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25101323 PMCID: PMC4102026 DOI: 10.1155/2014/837439
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1ROIs of striatum and occipital lobe in the TRODAT-1 SPECT of a 23-year-old woman (native space). (a) 70% threshold-ROI method and (b) SPECT-normalization approach.
Pearson product-moment correlation coefficients (bottom left) and ratios of the root-mean-square differences to the averages (top right) between quantification methods of measuring DAT availabilities.
| Method | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (1) MRI-delineation | — | 57% | 33% | 35% | 30% | 26% | 21% | 17% | 15% | 16% | 43% | 31% | 23% | 25% | 30% | 17% | 19% | 17% |
| (2) SPECT-delineation | 0.56 | — | 32% | 83% | 79% | 75% | 70% | 65% | 59% | 53% | 32% | 40% | 61% | 59% | 35% | 48% | 70% | 67% |
| (3) Template-ROI | 0.79 | 0.65 | — | 62% | 57% | 52% | 47% | 42% | 36% | 30% | 23% | 23% | 40% | 38% | 14% | 23% | 46% | 43% |
| (4) 90% Threshold-ROI | 0.74 | 0.50 | 0.70 | — | 5% | 11% | 17% | 23% | 30% | 37% | 71% | 59% | 40% | 43% | 59% | 44% | 21% | 24% |
| (5) 85% Threshold-ROI | 0.74 | 0.50 | 0.70 | 1.00 | — | 6% | 11% | 18% | 25% | 32% | 66% | 54% | 36% | 39% | 54% | 39% | 17% | 19% |
| (6) 80% Threshold-ROI | 0.74 | 0.50 | 0.71 | 1.00 | 1.00 | — | 6% | 12% | 19% | 26% | 61% | 50% | 32% | 35% | 49% | 34% | 13% | 15% |
| (7) 75% Threshold-ROI | 0.74 | 0.51 | 0.71 | 1.00 | 1.00 | 1.00 | — | 6% | 13% | 21% | 56% | 45% | 28% | 31% | 44% | 29% | 12% | 12% |
| (8) 70% Threshold-ROI | 0.75 | 0.51 | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | — | 7% | 14% | 51% | 39% | 25% | 28% | 38% | 23% | 13% | 12% |
| (9) 65% Threshold-ROI | 0.75 | 0.51 | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | — | 7% | 45% | 34% | 24% | 25% | 31% | 18% | 17% | 15% |
| (10) 60% Threshold-ROI | 0.76 | 0.52 | 0.73 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | — | 38% | 28% | 24% | 25% | 25% | 13% | 23% | 20% |
| (11) MRI-normalization | 0.78 | 0.55 | 0.70 | 0.74 | 0.74 | 0.74 | 0.74 | 0.75 | 0.75 | 0.75 | — | 14% | 39% | 36% | 18% | 31% | 55% | 51% |
| (12) MRI-norm., VC | 0.78 | 0.55 | 0.70 | 0.73 | 0.73 | 0.73 | 0.74 | 0.74 | 0.75 | 0.75 | 1.00 | — | 26% | 23% | 15% | 21% | 43% | 39% |
| (13) MRI-norm., GTM | 0.75 | 0.52 | 0.68 | 0.71 | 0.71 | 0.71 | 0.71 | 0.72 | 0.73 | 0.73 | 0.99 | 0.99 | — | 4% | 34% | 23% | 25% | 23% |
| (14) MRI-norm., RBV | 0.74 | 0.51 | 0.67 | 0.71 | 0.71 | 0.71 | 0.71 | 0.72 | 0.73 | 0.73 | 0.99 | 0.99 | 1.00 | — | 32% | 22% | 28% | 26% |
| (15) SPECT-norm. | 0.83 | 0.54 | 0.76 | 0.85 | 0.85 | 0.85 | 0.85 | 0.86 | 0.86 | 0.87 | 0.91 | 0.91 | 0.89 | 0.88 | — | 16% | 42% | 38% |
| (16) SPECT-norm., VC | 0.82 | 0.52 | 0.75 | 0.85 | 0.85 | 0.85 | 0.85 | 0.86 | 0.86 | 0.87 | 0.88 | 0.88 | 0.86 | 0.86 | 1.00 | — | 26% | 23% |
| (17) SPECT-norm., GTM | 0.80 | 0.47 | 0.74 | 0.84 | 0.84 | 0.84 | 0.84 | 0.85 | 0.85 | 0.85 | 0.84 | 0.85 | 0.83 | 0.82 | 0.98 | 0.99 | — | 4% |
| (18) SPECT-norm., RBV | 0.80 | 0.47 | 0.73 | 0.84 | 0.85 | 0.85 | 0.85 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.85 | 0.84 | 0.98 | 0.99 | 1.00 | — |
DAT: dopamine transporter; MRI: magnetic resonance imaging; SPECT: single photon emission-computed tomography; ROI: region of interest; norm.: normalization; GTM: geometric transfer matrix; RBV: region-based voxel-wise; VC: Van-Cittert deconvolution.
Comparison of the regression lines between quantification methods of measuring DAT availabilities.
| Method | Slope ( | Intercept | Decline per decade (95% CI∗∗) |
|
|---|---|---|---|---|
| (1) MRI-delineation | −0.015 (5.4 × 10−6) | 2.49 | 6.66% (4.34–8.52%) | 0.22 |
| (2) SPECT-delineation | −0.013 (1.7 × 10−5) | 1.62 | 9.47% (5.99–14.13%) | 0.20 |
| (3) Template-ROI | −0.011 (1.3 × 10−5) | 1.86 | 6.81% (4.52–8.77%) | 0.25 |
| (4) 90% Threshold-ROI | −0.018 (1.7 × 10−4) | 3.31 | 5.95% (3.34–8.10%) | 0.16 |
| (5) 85% Threshold-ROI | −0.017 (1.5 × 10−4) | 3.15 | 6.09% (3.46–8.29%) | 0.16 |
| (6) 80% Threshold-ROI | −0.017 (1.4 × 10−4) | 2.99 | 6.19% (3.63–8.45%) | 0.16 |
| (7) 75% Threshold-ROI | −0.016 (1.3 × 10−4) | 2.84 | 6.29% (3.60–8.63%) | 0.16 |
| (8) 70% Threshold-ROI | −0.015 (1.0 × 10−4) | 2.68 | 6.47% (3.45–8.73%) | 0.17 |
| (9) 65% Threshold-ROI | −0.015 (8.7 × 10−5) | 2.52 | 6.64% (3.62–9.10%) | 0.17 |
| (10) 60% Threshold-ROI | −0.014 (7.9 × 10−5) | 2.36 | 6.88% (3.86–9.42%) | 0.17 |
| (11) MRI-normalization | −0.018 (5.1 × 10−8) | 1.95 | 11.02% (7.98–13.66%) | 0.31 |
| (12) MRI-normalization with VC | −0.021 (5.5 × 10−8) | 2.24 | 11.17% (8.12–13.80%) | 0.30 |
| (13) MRI-normalization with GTM | −0.028 (1.7 × 10−7) | 2.89 | 11.85% (8.45–14.77%) | 0.29 |
| (14) MRI-normalization with RBV | −0.027 (3.8 × 10−7) | 2.80 | 11.99% (8.45–15.03%) | 0.27 |
| (15) SPECT-normalization | −0.014 (3.3 × 10−9) | 2.01 | 8.30% (6.15–9.90%) | 0.35 |
| (16) SPECT-normalization with VC | −0.017 (4.5 × 10−9) | 2.35 | 8.28% (6.18–9.93%) | 0.34 |
| (17) SPECT-normalization with GTM | −0.021 (1.2 × 10−8) | 3.01 | 7.99% (5.84–9.63%) | 0.33 |
| (18) SPECT-normalization with RBV | −0.020 (2.0 × 10−8) | 2.91 | 8.04% (5.87–9.71%) | 0.32 |
CI, confidence interval; DAT, dopamine transporter; MRI, magnetic resonance imaging; SPECT, single photon emission-computed tomography; ROI, region of interest; GTM, geometric transfer matrix; RBV, region-based voxel-wise; VC, Van-Cittert deconvolution.
*P-values for H 0: β 1 = 0.
**95% Confidence intervals for declines per decade using 10,000 bootstrap samples.
Figure 2Boxplots of the three groups: 18–30, 31–45, and 46–61 years old, in the 18 methods of determining striatal DAT availability. The high decline of DAT availability per decade determined by SPECT-delineation method (9.47%) was partly caused by outliners. There were six outliners (arrowheads) in the SPECT-delineation method. Instead of a two-sided normal distribution of the outliners, all the six outliners were less than the mean. It might thereby lead to a high decline of DAT availability per decade.
Striatal DAT availabilities, declines per decade of DAT availabilities, and striatum sizes in the transverse slices of the striatum ROIs defined by the atlas approaches.
| Transverse slices∗∗ | MRI-normalization | SPECT-normalization | ||||
|---|---|---|---|---|---|---|
| Average∗∗∗ | Decline per decade | Average size∗ | Average∗∗∗ | Decline per decade | Average size∗ | |
|
≤(OM | 1.46 | 5.12% | 68.4 | 1.54 | 4.15% | 78.3 |
| (OM | 1.78 | 6.19% | 57.7 | 1.86 | 5.74% | 67.4 |
| (OM | 1.76 | 7.67% | 76.4 | 1.81 | 7.17% | 87.2 |
| (OM | 1.64 | 8.30% | 89.8 | 1.66 | 8.04% | 97.1 |
| (OM | 1.44 | 9.41% | 92.7 | 1.47 | 8.89% | 94.3 |
| (OM | 1.21 | 10.34% | 87.5 | 1.25 | 10.29% | 80.7 |
| (OM | 0.99 | 11.56% | 73.8 | 1.04 | 11.51% | 60.8 |
| (OM | 0.79 | 11.84% | 56.9 | 0.85 | 12.70% | 41.2 |
|
≥(OM | 0.58 | 14.42% | 77.4 | 0.68 | 11.91% | 30.4 |
*Voxels: each voxel is of 2.897 mm × 2.897 mm × 2.897 mm.
**OM: the z axis of the OC mark is at the transverse slice with the largest striatum area.
***For comparisons, the same OC averages from the threshold-ROI methods were used in the calculation of (ST-OC)/OC.
Striatal DAT availabilities, declines per decade of DAT availabilities, and striatum sizes in the regions: (1) inside both the threshold ROIs and the atlas-defined ROIs, (2) inside the threshold ROIs but outside the atlas-defined ROIs, and (3) outside the threshold ROIs but inside the atlas-defined ROIs.
| Thresholds | Inside threshold, inside atlas | Inside threshold, outside atlas | Outside threshold, inside atlas | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Average∗∗∗∗ | Decline∗∗∗ | Size∗∗ | Average∗∗∗∗ | Decline∗∗∗ | Size∗∗ | Average∗∗∗∗ | Decline∗∗∗ | Size∗∗ | |
| 90% | 2.71, 2.68∗ | 5.04%, 5.93% | 33.8, 41.1 | 2.65, 2.62 | 6.00%, 6.10% | 15.8, 8.5 | 1.28, 1.40 | 9.43%, 7.59% | 646.8, 596.2 |
| 85% | 2.55, 2.56 | 6.13%, 6.06% | 69.4, 82.2 | 2.50, 2.48 | 6.11%, 6.23% | 42.0, 29.1 | 1.22, 1.33 | 9.54%, 7.97% | 611.3, 555.1 |
| 80% | 2.43, 2.43 | 6.28%, 6.08% | 113.4, 130.8 | 2.36, 2.33 | 6.17%, 6.43% | 84.6, 67.2 | 1.14, 1.24 | 9.77%, 8.28% | 567.2, 506.6 |
| 75% | 2.31, 2.32 | 6.40%, 6.17% | 162.2, 184.1 | 2.21, 2.19 | 6.27%, 6.47% | 150.4, 128.5 | 1.06, 1.15 | 10.03%, 8.75% | 518.4, 453.3 |
| 70% | 2.19, 2.20 | 6.54%, 6.21% | 215.9, 242.0 | 2.07, 2.04 | 6.46%, 6.68% | 246.6, 220.5 | 0.96, 1.05 | 10.51%, 9.30% | 464.7, 395.4 |
| 65% | 2.08, 2.10 | 6.68%, 6.25% | 270.0, 298.8 | 1.92, 1.89 | 6.64%, 6.84% | 377.0, 348.2 | 0.87, 0.95 | 11.02%, 9.99% | 410.6, 338.5 |
| 60% | 1.97, 2.00 | 6.82%, 6.29% | 325.4, 354.7 | 1.77, 1.75 | 6.90%, 7.07% | 550.6, 521.3 | 0.78, 0.85 | 11.70%, 10.79% | 355.2, 282.6 |
*In each pair of data, the left is for MRI-normalization, while the right is for SPECT-normalization.
**Size: each voxel is of 2.897 mm × 2.897 mm × 2.897 mm.
***Decline per decade.
****For comparisons, the same OC averages from the threshold-ROI methods were used in the calculation of (ST-OC)/OC.
Figure 3Decline per decade for each voxel in the MNI space. (a) MRI-normalization approach and (b) SPECT-normalization approach.